IX Biopharma (SGX:42C) has issued and allotted 1.7 million new shares under its performance share plan, increasing its total issued share count to 885 million, according to a Friday filing on the Singapore Exchange.

The shares, vested under grants announced in December and February, were not issued to directors or controlling shareholder. They rank pari passu with existing shares and are set to begin trading on Catalist on Feb. 25.